Bristol-Myers Squibb (NYSE:BMY) recently announced its plan to merge with Celgene in a $74 billion deal. The combined entity will have revenues of over $37 billion, and earnings could be as high as $6 per share in the coming years, according to our estimates. We have created an interactive dash...
Bristol-Myers Squibb (NYSE:BMY) recently announced its plan to merge with Celgene in a $74 billion deal. The combined entity will have revenues of over $37 billion, and earnings could be as high as $6 per share in the coming years, according to our estimates. We have created an interactive dash...
Share this Article
Recommended